For the quarter ending 2025-09-30, APUS had -$1,748,706 decrease in cash & cash equivalents over the period. -$1,748,706 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,781,255 | -3,064,590 |
| Stock-based compensation - common stock grants | 0 | 1,700,000 |
| Stock-based compensation - stock options | 42,674 | 192,053 |
| Change in fv of warrant liability | -12,859 | -9,518 |
| Depreciation expense of property and equipment | 1,489 | 232 |
| Accrued interest expense - related parties | 6,301 | 21,253 |
| Accretion expense | 1 | 39,832 |
| Prepaid expenses and other current and non-current assets | 431,011 | 1,788,619 |
| Accounts payable and accrued expenses | 448,494 | -472,052 |
| Net cash used in operating activities | -1,726,166 | -3,381,409 |
| Purchase of furniture and equipment | 22,540 | 13,369 |
| Net cash provided by investing activities | -22,540 | -13,369 |
| Cash proceeds from issuance of common stock in ipo | 0 | 11,953,046 |
| Proceeds from notes payable - related parties | 0 | 250,000 |
| Cash advances from related parties | 0 | 17,400 |
| Cash advances paid to related parties | 0 | 93,800 |
| Net cash provided by financing activities | 0 | 12,126,646 |
| Net increase (decrease) in cash | -1,748,706 | 8,731,868 |
| Cash and cash equivalents at beginning of period | 3,455 | - |
| Cash and cash equivalents at end of period | 6,986,617 | - |
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)